We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Haleon | LSE:HLN | London | Ordinary Share | GB00BMX86B70 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 3.20 | 0.79% | 409.00 | 12,050,779 | 16:35:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 408.50 | 408.60 | 411.40 | 405.90 | 407.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 11.23B | 1.44B | 0.1596 | 25.60 | 36.66B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:44:51 | O | 112,956 | 409.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/5/2025 | 07:00 | UK RNS | Haleon PLC Transaction in Own Shares |
| 19/5/2025 | 10:00 | UK RNS | Haleon PLC Director/PDMR Shareholding |
| 19/5/2025 | 07:00 | UK RNS | Haleon PLC Transaction in Own Shares |
| 16/5/2025 | 07:00 | UK RNS | Haleon PLC Transaction in Own Shares |
| 15/5/2025 | 14:25 | ALNC |  DIRECTOR DEALINGS: IAG execs sell GBP4 million in shares after results |
| 15/5/2025 | 07:00 | UK RNS | Haleon PLC Transaction in Own Shares |
| 14/5/2025 | 07:00 | UK RNS | Haleon PLC Transaction in Own Shares |
| 13/5/2025 | 16:15 | UK RNS | Haleon PLC Director/PDMR Shareholding |
| 13/5/2025 | 12:30 | UK RNS | Haleon PLC Director/PDMR Shareholding |
| 13/5/2025 | 07:00 | UK RNS | Haleon PLC Transaction in Own Shares |
Haleon (HLN) Share Charts1 Year Haleon Chart |
|
1 Month Haleon Chart |
Intraday Haleon Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:44:51 | 409.00 | 112,956 | 461,990.04 | O |
| 15:44:51 | 409.00 | 112,956 | 461,990.04 | O |
| 15:39:01 | 409.00 | 112,956 | 461,990.04 | O |
| 15:39:01 | 409.00 | 112,956 | 461,990.04 | O |
| 15:35:27 | 409.00 | 8,281 | 33,869.29 | O |
| Top Posts |
|---|
Posted at 20/5/2025 09:20 by Haleon Daily Update Haleon is listed in the Offices-holdng Companies,nec sector of the London Stock Exchange with ticker HLN. The last closing price for Haleon was 405.80p.Haleon currently has 9,034,076,586 shares in issue. The market capitalisation of Haleon is £36,904,202,854. Haleon has a price to earnings ratio (PE ratio) of 25.60. This morning HLN shares opened at 407p |
Posted at 04/5/2025 13:27 by santos123 I received an email on 30 April.Informing me the Matt Shattock, has been employed as non executive director. I remember him as Chairman of Dominoes Pizza (DOM) Not exactly a success there. Using last Fridays closing price of DOM:- 5 YEAR CHART -22.7% 10 YEAR CHART +0.90% Absolutely pathetic. I went to a Dominos Pizza A.G.M. a few years ago, asked 2 questions at the meeting about the financial report, that he refused to answer. How on earth do these people get jobs as Non-Executives ? Santos123. |
Posted at 10/4/2025 20:54 by cerrito Found this on Proactivequote Analysts at Citi and Barclays believe Haleon PLC (LSE:HLN, NYSE:HLN) is well positioned for the current uncertain climate, relatively protected from the worst of Donald Trump's new tariffs. Ahead of its first-quarter sales on 30 April, Citi described the consumer healthcare group as a solid defensive play for investors concerned about recession risks and the fallout from the US tariff regime. Barclays, meanwhile, also pitched Haleon as one of the most defensive stocks in its large-cap European consumer staples coverage, with tariff risk expected to have only a limited impact. Shares in the maker of household brands such as Sensodyne, Panadol and Centamin, have been under pressure amid broader worries over US consumer demand and a tough comparison with last year’s strong flu season. Citi sees those headwinds, including weaker volumes in the US vitamins market and later-than-usual flu reorder cycle, as already well flagged. It expects organic sales growth of 3.4% in the first quarter, enough to keep full-year forecasts intact. More importantly, the American bank highlights several reasons why Haleon stands out in today’s volatile environment. It estimates tariffs would shave just 20 basis points off gross profit, owing to the company’s limited direct exposure and the price resilience of its over-the-counter products. The group also generates strong free cash flow, allowing it to reduce net debt by about half a turn of EBITDA each year; something many peers will struggle to match if conditions tighten further. Looking ahead, analysts see a clear set of catalysts. A capital markets day (CMD) is due on 1 May, while US retail channels are expected to rebuild flu-related inventories in the second half, following a strong end to the 2024 season. The CMD's focus is expected to be on supply chain efficiency, Barclays noted, with chief supply chain officer Namrata Patel, who joined in November 2023, presenting. Barclays, which raised its price target to 452p from 445p, said: "Macro visibility is currently extremely limited, as such we like Haleon's relative insulation from both tariff risk and wider consumer weakness. "In the event of macro visibility and expectations improving, Haleon is likely to be left behind in any relief rally, but for now we find its defensiveness appealing." |
Posted at 08/4/2025 09:46 by philanderer Deutsche Bank Research cuts Haleon price target to 375 (390) pence - 'hold'HSBC cuts Haleon price target to 410 (420) pence - 'hold' Barclays raises Haleon price target to 452 (445) pence - 'overweight' UBS cuts Haleon price target to 443 (450) pence - 'buy' |
Posted at 01/4/2025 07:10 by laurence llewelyn binliner #PatientCapital, indeed, how many II sellers need to discount a sale to get it fully subscribed, not so at HLN, holding steady, a solid low yield growth stock but as debt comes back to their EBITDA multiple target the dividend should rise..New ISA day next week.. :o) |
Posted at 31/3/2025 19:05 by patientcapital Holding nicely above the placing price. |
Posted at 19/3/2025 09:15 by patientcapital Price holding steady. Pretty slick. |
Posted at 09/3/2025 14:47 by pdosullivan Not shooting the messenger here but the IC is not up with events in saying high leverage applies to HLN. At end-24 it had net debt of GBP7.9bn, 2.8x EBITDA, and down from GBP8.5bn at end-23. And during 2024 it spent GBP0.5bn on buybacks. HLN is throwing off cash and able to delever at a rapid enough clip if so minded. |
Posted at 14/11/2024 09:56 by anhar As an income investor I won't be adding at the current very low yield. Even a big rise in the divis of say 50% would still leave the yield too low for me to increase my holding with the share price around the present level. For most purchases, either top-ups or new holdings, I like to target a yield of at least 5% in current market conditions though I sometimes make exceptions to this for portfolio and diversification reasons.I continue though to retain my holding from the GSK demerger as I think HLN has decent potential divi growth and my favoured approach is to to nothing. |
Posted at 06/11/2024 09:27 by anhar No reasons, share prices mostly move randomly. |
Posted at 19/5/2024 10:04 by philanderer Yes, I would have thought so. This from early april.Haleon overhang can be gone in a year, suggests Barclays One of the biggest drags on the share price of consumer group Haleon might be gone by the end of the year suggests Barclays. According to the broker, and based on Pfizer's latest placing, it's possible it and GSK will have entirely sold down by the end of this year, leaving Haleon 100% free float, said the broker. “Given repeated investor feedback about the overhang being a barrier to share price performance, we think this could be a significantly helpful potential catalyst.” Currently, Pfizer has 2062m shares in Haleon (22.6%) and GSK has 385m (4.2%) for a total overhang of 27%, down from 45% in May 2023 before the first GSK placing. “The pace of sell-down is accelerating and our analysis shows Haleon could be overhang-free by year-end at the current rate of progress,” said the broker. “With a 90-day lockup from the Mar24 placing, there is time for three more placings before year-end, assuming the lockup remains unchanged. “Haleon also has £185m remaining in its announced buyback plans for this year, which is 57m shares at the current share price. This would leave an overhang of 18m shares, or 0.2% of Haleon, less than a rounding error.” Barclays sees the overhang as a key reason for Haleon’s strong sales performance since its split from GSK has failed to translate into a better share price performance. “When Haleon spun in summer 2022 there was considerable scepticism about its 4-6% organic sales growth target, yet that year it delivered 9%. “Then there was considerable scepticism about it delivering 4-6% in 2023 given the 9% comp, yet last year it delivered 8%. Barclays added that Haleon remains one of its most preferred names within European Consumer Staples, a sector it sees as highly attractive, and potentially consolidating. The broker has a price target of 390p for Haleon and an overweight rating. proactiveinvestors.c |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
